Second Primary Cancer After Bladder Cancer: A Comprehensive
Analysis of a National Cancer Registry

J 2025

Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry

BUCHLER, Tomas; Lucie PEHALOVA; Alina PIRSHTUK; Jan MUŽÍK; Marek BABJUK et al.

Základní údaje

Originální název

Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry

Autoři

BUCHLER, Tomas; Lucie PEHALOVA; Alina PIRSHTUK; Jan MUŽÍK; Marek BABJUK a Ladislav DUŠEK

Vydání

Cancer Medicine, Houston, John Wiley & Sons Ltd. 2025, 2045-7634

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.100 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00143760

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

bladder cancer; cancer registry; lung cancer; second primary cancer; survivorship

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 2. 2026 08:21, Mgr. Tereza Miškechová

Anotace

V originále

Background Bladder cancer (BC) is one of the most common cancers and many patients will experience long-term survival. Non-urothelial second primary cancers (SPC) relatively frequently occur in the population of BC survivors.Methods Czech National Cancer Registry was the principal data source for this study. The risk of development of non-urothelial SPC after BC was assessed by the standardized incidence ratio (SIR). The standardized mortality ratio (SMR) was utilized to determine the risk of death from SPC following BC.Results Of the total of 61,314 patients with BC, a cohort of 12,645 survivors diagnosed with a SPC were analyzed. Compared to the general population, the SIR of neoplasia was significantly increased in BC survivors, with a SIR of 1.75 (95% confidence interval [CI] 1.72-1.78) for all cancers, especially during the first 5 years after BC diagnosis. The SMR was increased in BC survivors (1.25; 95% CI 1.21-1.29) for all cancers. Lung cancer frequently occurred as a SPC and was associated with high mortality in BC survivors. BC survivors also had a higher risk of laryngeal cancer and other cancers known to be strongly associated with smoking, but also of soft tissue tumors, colorectal cancer, chronic lymphocytic leukemia, and thyroid cancer.Conclusions The present large registry-based study shows that BC survivors have a significantly higher risk of being diagnosed with another primary cancer compared to the general population, especially during the first 5 years after BC diagnosis. In addition to smoking-related cancers, increased incidence of some cancers not known to be associated with smoking was observed.

Citovat

BUCHLER, Tomas; Lucie PEHALOVA; Alina PIRSHTUK; Jan MUŽÍK; Marek BABJUK a Ladislav DUŠEK. Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry. Cancer Medicine. Houston: John Wiley & Sons Ltd., 2025, roč. 14, č. 23, s. 1-10. ISSN 2045-7634. Dostupné z: https://doi.org/10.1002/cam4.71427.

@article{2556385,
   author = {Buchler, Tomas and Pehalova, Lucie and Pirshtuk, Alina and Mužík, Jan and Babjuk, Marek and Dušek, Ladislav},
   article_location = {Houston},
   article_number = {23},
   doi = {https://doi.org/10.1002/cam4.71427},
   keywords = {bladder cancer; cancer registry; lung cancer; second primary cancer; survivorship},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/cam4.71427},
   volume = {14},
   year = {2025}
}

TY  - JOUR
ID  - 2556385
AU  - Buchler, Tomas - Pehalova, Lucie - Pirshtuk, Alina - Mužík, Jan - Babjuk, Marek - Dušek, Ladislav
PY  - 2025
TI  - Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry
JF  - Cancer Medicine
VL  - 14
IS  - 23
SP  - 1-10
EP  - 1-10
PB  - John Wiley & Sons Ltd.
SN  - 20457634
KW  - bladder cancer
KW  - cancer registry
KW  - lung cancer
KW  - second primary cancer
KW  - survivorship
UR  - https://onlinelibrary.wiley.com/doi/10.1002/cam4.71427
N2  - Background Bladder cancer (BC) is one of the most common cancers and many patients will experience long-term survival. Non-urothelial second primary cancers (SPC) relatively frequently occur in the population of BC survivors.Methods Czech National Cancer Registry was the principal data source for this study. The risk of development of non-urothelial SPC after BC was assessed by the standardized incidence ratio (SIR). The standardized mortality ratio (SMR) was utilized to determine the risk of death from SPC following BC.Results Of the total of 61,314 patients with BC, a cohort of 12,645 survivors diagnosed with a SPC were analyzed. Compared to the general population, the SIR of neoplasia was significantly increased in BC survivors, with a SIR of 1.75 (95% confidence interval [CI] 1.72-1.78) for all cancers, especially during the first 5 years after BC diagnosis. The SMR was increased in BC survivors (1.25; 95% CI 1.21-1.29) for all cancers. Lung cancer frequently occurred as a SPC and was associated with high mortality in BC survivors. BC survivors also had a higher risk of laryngeal cancer and other cancers known to be strongly associated with smoking, but also of soft tissue tumors, colorectal cancer, chronic lymphocytic leukemia, and thyroid cancer.Conclusions The present large registry-based study shows that BC survivors have a significantly higher risk of being diagnosed with another primary cancer compared to the general population, especially during the first 5 years after BC diagnosis. In addition to smoking-related cancers, increased incidence of some cancers not known to be associated with smoking was observed.
ER  -

BUCHLER, Tomas; Lucie PEHALOVA; Alina PIRSHTUK; Jan MUŽÍK; Marek BABJUK a Ladislav DUŠEK. Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry. \textit{Cancer Medicine}. Houston: John Wiley \&{} Sons Ltd., 2025, roč.~14, č.~23, s.~1-10. ISSN~2045-7634. Dostupné z: https://doi.org/10.1002/cam4.71427.

Přehled o publikaci